메뉴 건너뛰기




Volumn 10, Issue 4, 2011, Pages 280-291

The use of bisphosphonates in women prior to or during pregnancy and lactation

Author keywords

Bisphosphonates; Lactation; Pregnancy

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; CYCLOSPORIN; ETIDRONIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; MEDRONATE TECHNETIUM TC 99M; MORPHINE; NERIDRONIC ACID; PAMIDRONIC ACID; RADIOISOTOPE; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

EID: 84855517874     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1319     Document Type: Article
Times cited : (100)

References (44)
  • 2
    • 51349163043 scopus 로고    scopus 로고
    • Bisphosphonates: Mechanism of action and role in clinical practice
    • Drake MT, Clarke BL, Khosla S, 2008 Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032-1045.
    • (2008) Mayo Clin Proc , vol.83 , pp. 1032-1045
    • Drake, M.T.1    Clarke, B.L.2    Khosla, S.3
  • 3
    • 0032766937 scopus 로고    scopus 로고
    • Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats
    • Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A, 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60: 68-73.
    • (1999) Teratology , vol.60 , pp. 68-73
    • Patlas, N.1    Golomb, G.2    Yaffe, P.3    Pinto, T.4    Breuer, E.5    Ornoy, A.6
  • 4
    • 0027284434 scopus 로고
    • Effects of the bisphosphonate, alendronate, on parturition in the rat
    • Minsker DH, Manson JM, Peter CP, 1993 Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121: 217-223.
    • (1993) Toxicol Appl Pharmacol , vol.121 , pp. 217-223
    • Minsker, D.H.1    Manson, J.M.2    Peter, C.P.3
  • 6
    • 33749595622 scopus 로고    scopus 로고
    • The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment
    • Ornoy A, Wajnberg R, Diav-Citrin O, 2006 The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22: 578-579.
    • (2006) Reprod Toxicol , vol.22 , pp. 578-579
    • Ornoy, A.1    Wajnberg, R.2    Diav-Citrin, O.3
  • 7
    • 59849124507 scopus 로고    scopus 로고
    • Pregnancy outcome following in utero exposure to bisphosphonates
    • Levy S, Fayez I, Taguchi N, et al, 2009 Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44: 428-430.
    • (2009) Bone , vol.44 , pp. 428-430
    • Levy, S.1    Fayez, I.2    Taguchi, N.3
  • 8
    • 77952745140 scopus 로고    scopus 로고
    • Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?
    • Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A, 2010 Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev 9: 547-552.
    • (2010) Autoimmun Rev , vol.9 , pp. 547-552
    • Losada, I.1    Sartori, L.2    di Gianantonio, E.3    Zen, M.4    Clementi, M.5    Doria, A.6
  • 9
    • 33744953434 scopus 로고    scopus 로고
    • Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases
    • Chan B, Zacharin M, 2006 Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91: 2017-2020.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 2017-2020
    • Chan, B.1    Zacharin, M.2
  • 10
    • 21344456854 scopus 로고    scopus 로고
    • Maternal and fetal outcome after long-term pamidronate treatment before conception: A report of two cases
    • Munns CF, Rauch F, Ward L, Glorieux FH, 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742-1745.
    • (2004) J Bone Miner Res , vol.19 , pp. 1742-1745
    • Munns, C.F.1    Rauch, F.2    Ward, L.3    Glorieux, F.H.4
  • 11
    • 77950959084 scopus 로고    scopus 로고
    • Maternal and fetal outcome after long-term bisphosphonate exposure before conception
    • Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N, 2010 Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int 21: 709-710.
    • (2010) Osteoporos Int , vol.21 , pp. 709-710
    • Hassen-Zrour, S.1    Korbaa, W.2    Bejia, I.3    Saidani, Z.4    Bergaoui, N.5
  • 12
    • 0035878618 scopus 로고    scopus 로고
    • Osteoporosis and multiple pregnancy--a case report with positive outcome
    • Harsch IA, Hubner RH, Hahn EG, Hensen J, 2001 [Osteoporosis and multiple pregnancy--a case report with positive outcome]. Med Klin (Munich) 96: 402-407.
    • (2001) Med Klin (Munich) , vol.96 , pp. 402-407
    • Harsch, I.A.1    Hubner, R.H.2    Hahn, E.G.3    Hensen, J.4
  • 13
  • 14
    • 84863525145 scopus 로고    scopus 로고
    • Pregnancy-associated spinal osteoporosis treated with bisphosphonates: Long-term follow-up of maternal and infants outcome
    • in press
    • Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M, 2011 Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int, in press.
    • (2011) Rheumatol Int
    • Vujasinovic-Stupar, N.1    Pejnovic, N.2    Markovic, L.3    Zlatanovic, M.4
  • 15
    • 34548437078 scopus 로고    scopus 로고
    • Maternal and fetal outcome of pamidronate treatment before conception: A case report
    • Cabar FR, Nomura RM, Zugaib M, 2007 Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol 25: 344-345.
    • (2007) Clin Exp Rheumatol , vol.25 , pp. 344-345
    • Cabar, F.R.1    Nomura, R.M.2    Zugaib, M.3
  • 17
    • 78149409812 scopus 로고    scopus 로고
    • Intravenous bisphosphonate treatment and pregnancy: Its effects on mother and infant bone health
    • Mastaglia SR, Watman NP, Oliveri B, 2010 Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. Osteoporos Int 21: 1959-1962.
    • (2010) Osteoporos Int , vol.21 , pp. 1959-1962
    • Mastaglia, S.R.1    Watman, N.P.2    Oliveri, B.3
  • 18
    • 0042707523 scopus 로고    scopus 로고
    • Pharmacovigilance study of alendronate in England
    • Biswas PN, Wilton LV, Shakir SA, 2003 Pharmacovigilance study of alendronate in England. Osteoporos Int 14: 507-514.
    • (2003) Osteoporos Int , vol.14 , pp. 507-514
    • Biswas, P.N.1    Wilton, L.V.2    Shakir, S.A.3
  • 19
    • 0025187606 scopus 로고
    • Antenatal administration of aminopropylidene diphosphonate
    • Dunlop DJ, Soukop M, McEwan HP, 1990 Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49: 955.
    • (1990) Ann Rheum Dis , vol.49 , pp. 955
    • Dunlop, D.J.1    Soukop, M.2    McEwan, H.P.3
  • 20
    • 0029789509 scopus 로고    scopus 로고
    • Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate
    • Illidge TM, Hussey M, Godden CW, 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257-258.
    • (1996) Clin Oncol (R Coll Radiol) , vol.8 , pp. 257-258
    • Illidge, T.M.1    Hussey, M.2    Godden, C.W.3
  • 21
    • 4644310824 scopus 로고    scopus 로고
    • Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer
    • Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D, 2004 Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol 95: 252-255.
    • (2004) Gynecol Oncol , vol.95 , pp. 252-255
    • Andreadis, C.1    Charalampidou, M.2    Diamantopoulos, N.3    Chouchos, N.4    Mouratidou, D.5
  • 22
    • 33748105239 scopus 로고    scopus 로고
    • Malignant hypercalcemia in pregnancy: Effect of pamidronate on uterine contractions
    • Culbert EC, Schfirin BS, 2006 Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol 108: 789-791.
    • (2006) Obstet Gynecol , vol.108 , pp. 789-791
    • Culbert, E.C.1    Schfirin, B.S.2
  • 23
    • 0033815510 scopus 로고    scopus 로고
    • Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding
    • Siminoski K, Fitzgerald AA, Flesch G, Gross MS, 2000 Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15: 2052-2055.
    • (2000) J Bone Miner Res , vol.15 , pp. 2052-2055
    • Siminoski, K.1    Fitzgerald, A.A.2    Flesch, G.3    Gross, M.S.4
  • 24
  • 25
    • 0022883887 scopus 로고
    • Incidental diagnosis of pregnancy on bone and gallium scintigraphy
    • Palestro CJ, Malat J, Collica CJ, Richman AH, 1986 Incidental diagnosis of pregnancy on bone and gallium scintigraphy. J Nucl Med 27: 370-372.
    • (1986) J Nucl Med , vol.27 , pp. 370-372
    • Palestro, C.J.1    Malat, J.2    Collica, C.J.3    Richman, A.H.4
  • 26
    • 0027992077 scopus 로고
    • Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation
    • McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ, 1994 Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 35: 1338-1341.
    • (1994) J Nucl Med , vol.35 , pp. 1338-1341
    • McKenzie, A.F.1    Budd, R.S.2    Yang, C.3    Shapiro, B.4    Hicks, R.J.5
  • 27
    • 0034009975 scopus 로고    scopus 로고
    • A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy
    • Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD, 2000 A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 15: 557-563.
    • (2000) J Bone Miner Res , vol.15 , pp. 557-563
    • Black, A.J.1    Topping, J.2    Durham, B.3    Farquharson, R.G.4    Fraser, W.D.5
  • 29
    • 33646089442 scopus 로고    scopus 로고
    • Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
    • Nancollas GH, Tang R, Phipps RJ, et al, 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617-627.
    • (2006) Bone , vol.38 , pp. 617-627
    • Nancollas, G.H.1    Tang, R.2    Phipps, R.J.3
  • 30
    • 0035146537 scopus 로고    scopus 로고
    • Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
    • Dunford JE, Thompson K, Coxon FP, et al, 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242.
    • (2001) J Pharmacol Exp Ther , vol.296 , pp. 235-242
    • Dunford, J.E.1    Thompson, K.2    Coxon, F.P.3
  • 31
    • 0029886359 scopus 로고    scopus 로고
    • Bisphosphonates: A review of their pharmacokinetic properties
    • Lin JH, 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75-85.
    • (1996) Bone , vol.18 , pp. 75-85
    • Lin, J.H.1
  • 32
    • 22244432201 scopus 로고    scopus 로고
    • Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis
    • Cremers SC, Pillai G, Papapoulos SE, 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551-570.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 551-570
    • Cremers, S.C.1    Pillai, G.2    Papapoulos, S.E.3
  • 33
    • 36549010158 scopus 로고    scopus 로고
    • Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates
    • Kimmel DB, 2007 Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86: 1022-1033.
    • (2007) J Dent Res , vol.86 , pp. 1022-1033
    • Kimmel, D.B.1
  • 34
    • 0030766092 scopus 로고    scopus 로고
    • Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
    • Khan SA, Kanis JA, Vasikaran S, et al, 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12: 1700-1707.
    • (1997) J Bone Miner Res , vol.12 , pp. 1700-1707
    • Khan, S.A.1    Kanis, J.A.2    Vasikaran, S.3
  • 35
    • 33847734705 scopus 로고    scopus 로고
    • Prolonged bisphosphonate release after treatment in children
    • Papapoulos SE, Cremers SC, 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356: 1075-1076.
    • (2007) N Engl J Med , vol.356 , pp. 1075-1076
    • Papapoulos, S.E.1    Cremers, S.C.2
  • 36
    • 80052283962 scopus 로고    scopus 로고
    • Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover
    • Peris P, Torra M, Olivares V, et al, 2011 Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49: 706-709.
    • (2011) Bone , vol.49 , pp. 706-709
    • Peris, P.1    Torra, M.2    Olivares, V.3
  • 37
    • 0041331740 scopus 로고    scopus 로고
    • Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal
    • Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C, 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33: 301-307.
    • (2003) Bone , vol.33 , pp. 301-307
    • Bagger, Y.Z.1    Tanko, L.B.2    Alexandersen, P.3    Ravn, P.4    Christiansen, C.5
  • 38
    • 0028806469 scopus 로고
    • Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate
    • Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE, 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 3465-3468.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 3465-3468
    • Landman, J.O.1    Hamdy, N.A.2    Pauwels, E.K.3    Papapoulos, S.E.4
  • 39
    • 12144289279 scopus 로고    scopus 로고
    • Ten years' experience with alendronate for osteoporosis in postmenopausal women
    • Bone HG, Hosking D, Devogelaer JP, et al, 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.
    • (2004) N Engl J Med , vol.350 , pp. 1189-1199
    • Bone, H.G.1    Hosking, D.2    Devogelaer, J.P.3
  • 40
    • 33845890326 scopus 로고    scopus 로고
    • Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial
    • Black DM, Schwartz AV, Ensrud KE, et al, 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
    • (2006) JAMA , vol.296 , pp. 2927-2938
    • Black, D.M.1    Schwartz, A.V.2    Ensrud, K.E.3
  • 41
    • 38849130073 scopus 로고    scopus 로고
    • Fracture risk remains reduced one year after discontinuation of risedronate
    • Watts NB, Chines A, Olszynski WP, et al, 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365-672.
    • (2008) Osteoporos Int , vol.19 , pp. 365-672
    • Watts, N.B.1    Chines, A.2    Olszynski, W.P.3
  • 42
    • 84855512805 scopus 로고
    • Paschalidis eds, Athens
    • Guyton A 1992. Medical Physiology, Paschalidis eds, Athens; pp, 1205-1207.
    • (1992) Medical Physiology , pp. 1205-1207
    • Guyton, A.1
  • 43
    • 64049104797 scopus 로고    scopus 로고
    • Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial
    • Reid DM, Devogelaer JP, Saag K, et al, 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253-1263.
    • (2009) Lancet , vol.373 , pp. 1253-1263
    • Reid, D.M.1    Devogelaer, J.P.2    Saag, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.